Inventor · disambiguated record
Dmitry I. Gabrilovich
Also filed as: GABRILOVICH DMITRY · GABRILOVICH DMITRY I
9 granted patents·14 pending applications·9 citations·filing 2002–2025
81Inventor score
Files withWISTAR INST10H LEE MOFFITT CANCER CT & RES4ACTIVE BIOTECH AB2VANDERBILT UNIVERSITY AND INTR2ANTONIA SCOTT1
Top patents by PatentIndex Score
23 records- 0181US10414810B2Double mutant survivin vaccineH LEE MOFFITT CANCER CT & RES·Filed 2016·Granted Sep 17, 2019·2 cites·10 claims
- 0279US8668905B2P53 vaccines for the treatment of cancersANTONIA SCOTT·Filed 2006·Granted Mar 11, 2014·3 cites·35 claims
- 0378US9956212B2Quinoline carboxamides for use in the treatment of multiple myelomaACTIVE BIOTECH AB·Filed 2015·Granted May 1, 2018·4 cites·20 claims
- 0475US2025213659A1Use of lactoferrin for generating myeloid-derived suppressor cellsWISTAR INST·Filed 2024·Application pending·0 cites
- 0573US12344642B2Variant survivin vaccine for treatment of myelomaH LEE MOFFITT CANCER CT & RES·Filed 2021·Granted Jul 1, 2025·0 cites·12 claims
- 0672US11149072B2Variant survivin vaccine for treatment of myelomaH LEE MOFFITT CANCER CT & RES·Filed 2019·Granted Oct 19, 2021·0 cites·19 claims
- 0770US12295990B2Use of lactoferrin for generating myeloid-derived suppressor cellsWISTAR INST·Filed 2019·Granted May 13, 2025·0 cites·17 claims
- 0868US2025179132A1Variant survivin vaccine for treatment of cancerH LEE MOFFITT CANCER CT & RES·Filed 2025·Application pending·0 cites
- 0962US10314836B2Quinoline carboxamides for use in the treatment of multiple myelomaACTIVE BIOTECH AB·Filed 2018·Granted Jun 11, 2019·0 cites·12 claims
- 1060US2015044240A1P53 vaccines for the treatment of cancersUNIV SOUTH FLORIDA·Filed 2014·Application pending·0 cites
- 1157US2006063697A1Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responsesGABRILOVICH DMITRY·Filed 2005·Application pending·0 cites
- 1257US2005171045A1Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responsesVANDERBILT UNIVERSITY AND INTR·Filed 2004·Application pending·0 cites
- 1355US12146156B2Use of LRP2 agonists for generating myeloid-derived suppressor cellsWISTAR INST·Filed 2020·Granted Nov 19, 2024·0 cites·13 claims
- 1455US2021318310A1Methods for monitoring polymorphonuclear myeloid derived suppressor cellsThe Wistar Insitute of Anatomy and Biology·Filed 2021·Application pending·0 cites
- 1555US2021148916A1Methods for Monitoring Polymorphonuclear Myeloid Derived Suppressor Cells and Compositions and Methods of Treatment of CancerWISTAR INST·Filed 2020·Application pending·0 cites
- 1651US11073521B2Methods for monitoring polymorphonuclear myeloid derived suppressor cellsWISTAR INST·Filed 2016·Granted Jul 27, 2021·0 cites·9 claims
- 1751US2003045499A1Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responsesVANDERBILT UNIVERSITY AND INTR·Filed 2002·Application pending·0 cites
- 1851US2023151434A1Reawakening of dormant tumor cells by modified lipids derived from stress activated neutrophilsWISTAR INST·Filed 2021·Application pending·0 cites
- 1949US2022381787A1Novel lox-1 antibody compositions, lox1 neutralization assay and methods of treatment using sameWISTAR INST·Filed 2020·Application pending·0 cites
- 2048US2018059115A1Methods for monitoring polymorphonuclear myeloid derived suppressor cells, and compositions and methods of treatment of cancerWISTAR INST·Filed 2017·Application pending·0 cites
- 2148US2021346326A1Compositions and methods for altering neutrophil migration and metastasisWISTAR INST·Filed 2019·Application pending·0 cites
- 2245US2022267770A1Compositions and methods of using c/ebp alpha sarnaMINA THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 2339US2022096484A1Methods and compositions for treating cancer by targeting fatp2 and myeloid derived suppressor cellsWISTAR INST·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Dmitry I. Gabrilovich files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →